Rebetol and Intron A Combination Therapy Articles
Schering-Plough cash-flow questions
18 August 2003
ICN Pharma posts 4th-qtr EPS loss of $1.20
17 March 2003
Ribapharm sues Roche for patent infringement
12 August 2002
Ribapharm confident on 2nd-qtr results
15 July 2002
Stock Commentary - New York
27 May 2002
Infergen outdoes Rebetron in Phase IV study
15 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
ICN Pharma earnings take a downturn
3 August 2001
FDA approves Rebetol as separate treatment
31 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
S-P looking for royalty refund from ICN
11 July 2001
Manufacturing woes hit Schering-Plough
18 April 2001
EU extends Remicade indications
7 February 2001
Schering-Plough EPS increases 14.7%
26 January 2001
ICN Pharma profits continue to climb
7 November 2000
S-P sales growth driven by Claritin
24 October 2000
ICN 2nd-qtr revenues pushing $200 million
7 August 2000
Schering-Plough net income up 16%
26 July 2000
Schering-Plough net income rises 16.5%
26 April 2000
Stock Commentary New York
9 March 2000
ICN revenues boosted by Rebetron
3 March 2000
ICN Pharma set to spend more on R&D
27 January 2000
ICN revenues benefit from Rebetron
9 November 1999
Schering-Plough strong sales boost EPS
22 October 1999
Rebetron gets first-line approval in Canada
5 May 1999
ICN Pharma $10 million stock buyback
19 April 1999
Roferon A works with ribavirin in HCV
15 April 1999
Schering-Plough buys $27 mill of ICN stock
9 April 1999
Stock Commentary New York
11 March 1999
ICN hit by $230 million charge in Yugoslavia
8 March 1999
Enzon - improving the delivery and side effect profile of proven
20 January 1999
Rebetron Indications Expanded Into HCV
16 December 1998
AASLD Conference - Focus On HCV/HBV By Lehman
1 December 1998
ICN Hit Hard By Crises in Eastern Europe & Russia
10 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
S-P Files For Temodal In The USA
20 August 1998
Standard & Poor's Impressed With ICN
7 August 1998
Schering-Plough Files sNDA For Rebetron
18 June 1998
Stock Commentary New York
15 June 1998
FDA Clears Rebetron, New Therapy For Hepatitis C
15 June 1998
Showing 1-54 of 54 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
